津力达颗粒降糖作用部分依赖巴马汀激活FGFR1通路
本研究采用表面等离子共振垂钓技术从津力达颗粒中鉴定出可结合FGFR1的巴马汀,体内外实验显示巴马汀激活FGFR1磷酸化并上调GLUT-1,促进胰岛素抵抗HepG2细胞摄糖并缓解糖尿病小鼠高血糖,提示津力达降糖部分依赖巴马汀激活FGFR1通路。
要点
- 津力达颗粒降糖机制部分依赖巴马汀激活FGFR1通路。
- 巴马汀可上调GLUT-1表达促进胰岛素抵抗细胞摄糖。
- 巴马汀在糖尿病小鼠中可缓解高血糖。
核心结论
- 巴马汀是津力达颗粒中结合FGFR1的活性成分,作为FGFR1激活剂发挥降糖作用。
- 津力达颗粒的降糖效应部分依赖于巴马汀诱导的FGFR1通路激活。
研究设计与样本
- 采用表面等离子共振垂钓技术从津力达颗粒中筛选结合FGFR1的分子。
- 通过体内和体外实验验证巴马汀对FGFR1磷酸化、GLUT-1表达及降糖效应的影响。
主要发现
- 巴马汀可显著刺激FGFR1磷酸化并上调GLUT-1表达。
- 巴马汀促进胰岛素抵抗HepG2细胞摄取葡萄糖。
- 巴马汀缓解糖尿病小鼠高血糖。
临床怎么用
- 津力达颗粒的降糖作用部分通过巴马汀激活FGFR1通路实现,为临床辨证使用提供分子依据。
- 巴马汀可作为FGFR1激活剂用于糖尿病治疗的进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JinQi Jiangtang tablet (JQJTT) is a Chinese patent medicine that has been shown to be beneficial for patients with diabetes both preclinically and clinically; however, the molecular mechanism underlying the effects of JQJTT remains unclear. In this study, surface plasmon resonance fishing was employed to identify JQJTT constituent molecules that can specifically bind to fibroblast growth factor receptor 1 (FGFR1), leading to the retrieval of palmatine (PAL), a key active ingredient of JQJTT. In vivo and in vitro experiments demonstrated that PAL can significantly stimulate FGFR1 phosphorylation and upregulate glucose transporter type 1 (GLUT-1) expression, thereby facilitating glucose uptake in insulin resistance (IR) HepG2 cells as well as alleviating hyperglycemia in diabetic mice. Our results revealed that PAL functions as an FGFR1 activator and that the hypoglycemic effect of JQJTT is partially dependent on the PAL-induced activation of the FGFR1 pathway. In addition, this study contributed to the understanding the pharmacodynamic basis and mechanism of action of JQJTT and provided a novel concept for future research on PAL.
引用
- Li S, Li X, Wang H, et al. The Hypoglycemic Effect of JinQi Jiangtang Tablets Is Partially Dependent on the Palmatine-Induced Activation of the Fibroblast Growth Factor Receptor 1 Signaling Pathway. Front Pharmacol. 2022. PMID: 35935824. doi:10.3389/fphar.2022.895724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。